The disclosure relates, in general, to treatment of fatty liver disorders comprising administering compositions comprising cysteamine products. The disclosure provides administration of enterically coated cysteamine compositions to treat fatty liver disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).本揭示案大體而言係關於治療脂肪肝病症,該治療包含投與包含半胱胺產物之組合物。本揭示案提供投與腸溶性包覆之半胱胺組合物以治療脂肪肝病症,諸如非酒精性脂肪肝病(NAFLD)及非酒精性脂肪肝炎(NASH)。